REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization
Latest Information Update: 15 Jun 2022
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REDO
- 10 Jun 2022 Results of post-hoc analysis published in the Rheumatology
- 12 Jan 2022 Results (n=140)of secondary analysis investigating associations between rituximab dosage, drug levels, anti-drug antibodies and B cell counts and predicting value of pharmacokinetic and dynamic parameters, published in the Rheumatology
- 31 Aug 2019 Status changed from recruiting to completed.